Coxsackievirus B group 5 type with oncolytic effect and its application
Through the combination of the Faulkner strain of the COSAC Group B group B and DNA-PK or ATM inhibitor, the problem of insufficient effectiveness of existing oncolytic viruses in the treatment of p53-expressing tumor cells was solved, and the tumor cells was significantly improved The killing efficacy and survival period have achieved effective treatment for tumors such as lung cancer and liver cancer.
Patent Information
- Application Number
- CN202211145120.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-09-20
AI Technical Summary
Existing oncolytic viruses have abnormal activation of signaling pathways in the treatment of tumors, resulting in weakening of oncolytic effects and lack of effective specific pathway inhibitors, especially in the treatment of p53-expressing tumor cells.
The combination of the Faulkner strain of Coxsackie virus group B and DNA-PK inhibitor NU7441 or ATM inhibitor KU60019 is used to prepare drugs for treating tumors, by increasing the percentage of specific T cells and NK cells in tumor tissues. Induce the infiltration of CD4+ T cells and CD8+ T cells in tumors, and verify their therapeutic effects through cytotoxic experiments and animal models.
It significantly improves the killing efficacy of tumor cells such as lung cancer, liver cancer, cervical cancer, and prolongs survival. The combination of DNA-PK or ATM inhibitors can enhance the oncolytic effect of the virus, especially in tumor cells with high p53 expression. There is a significant effect of ER-dependent synergistic enhancement.
Smart Images

Figure CN115518082B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology and targeted drug technology, and in particular to a Coxsackievirus B group 5 type with oncolytic effect, and also to the use of the virus in preparing drugs. Background Art
[0002] Oncolytic viruses refer to a class of natural or genetically modified viruses that can selectively replicate in tumor cells and dissolve tumor cells without damaging normal tissues. Currently, there are four oncolytic viruses on the market worldwide for the treatment of malignant melanoma, head and neck cancer, etc.
[0003] Enterovirus (EV) is the main pathogen that causes infantile hand, foot and mouth disease, herpetic pharyngitis, onychomycosis, myocarditis, aseptic meningitis and other diseases. According to its genetic and antigenic characteristics, it can be divided into 12 groups, including EV-AH, J and rhinovirus AC. EV receptors include poliovirus receptor (PVR), intercellular adhesion molecule-1 (ICAM-1), coxsackievirus and adenovirus receptor (CAR), decay accelerating factor (DAF), scavenger receptor 2, heparan sulfate, etc. Related studies have confirmed that some EV receptors are overexpressed on the surface of certain tumor cells, giving natural enterovirus oncolytic and selective killing effects. Enteroviruses with oncolytic effects that have been discovered include coxsackievirus A21 (CV-A21), echovirus type 7 (ECHO 7), poliovirus (PV), coxsackievirus group B type 3 (CV-B3), etc. Among them, ECHO 7 (trade name: ) has been approved for marketing in Latvia and other countries for the treatment of early malignant melanoma, CV-A21 (trade name: ) and PV have entered the clinical trial stage. Different types of EVs have different receptors. For example, PV can use highly expressed PVR to infect and kill malignant glioma cells, and CV-A21 uses highly expressed ICAM-1 and DAF to infect breast cancer, colorectal cancer, pancreatic cancer and other cell lines, but has no toxicity or only weak toxicity to the corresponding normal tissues.
[0004] After oncolytic viruses infect host cells through specific receptors, they release a large number of pathogen-associated molecular patterns and damage-associated molecular patterns through replication, activate innate and adaptive immune responses, produce a large number of cytokines and chemokines, and recruit lymphocytes to change the immunosuppressive state in tumor tissues. Study on the oncolytic effect and antigen detection reagents of coxsackieviruses (Cui Bopei, 2020) screened and evaluated oncolytic coxsackieviruses, and found that coxsackievirus group B type 5 (CV-B5) has a therapeutic effect in nude mouse tumor-bearing animal models. However, tumor cells have abnormal activation of many signaling pathways, which greatly weakens the oncolytic effect of the virus. At present, there is a lack of research on the use of inhibitors of specific pathways in combination with this virus. Summary of the invention
[0005] The purpose of the present invention is to provide an oncolytic virus that has therapeutic significance for lung cancer tumors, and to verify the effect of combining it with an inhibitor of a specific pathway.
[0006] Based on this, the present invention provides the use of the CV-B5 Faulkner strain in the preparation of a drug for human lung cancer tumors, wherein the tumors also include liver cancer cells, pancreatic cancer cells, cervical cancer cells, and the like.
[0007] It is especially used to increase the percentage of specific T cells and NK cells in tumor tissues, and to induce CD4 + T cells, CD8 + Infiltration of T cells and NK cells.
[0008] On the other hand, the present invention also provides the use of the combination of Coxsackievirus group B type 5 Faulkner strain and DNA-PK inhibitor in the preparation of drugs for treating tumors.
[0009] According to a preferred embodiment, the DNA-PK inhibitor is NU7441.
[0010] Preferably, this drug is used for oncolysis of tumor cells expressing p53, such as human large cell lung cancer cells (NCI-H460).
[0011] The present invention also provides the use of the combination of Coxsackievirus B group 5 type Faulkner strain and ATM inhibitor in the preparation of drugs for treating tumors.
[0012] According to another preferred embodiment, the ATM inhibitor is KU60019.
[0013] Similarly, the drug was applied to oncolysis of tumor cells expressing p53, such as human large cell lung cancer cells (NCI-H460).
[0014] The present invention preliminarily studies the oncolytic effects of group A and group B coxsackie viruses such as CV-B3 / Nancy, CV-B3 / 112, CV-B5 / Faulkner, CV-B5 / JS417 and CV-A6 / Gdula through cytotoxic experiments. The results show that except for CV-A6 which only exhibits a weak oncolytic effect, the other four viruses can significantly kill lung cancer cells, liver cancer cells, cervical cancer cells, etc., but only CV-B5 / Faulkner and CV-B5 / JS417 do not infect normal lung tissue cells at 1 MOI, and can significantly kill A549, NCI-H1299, NCI-H460 and other lung cancer cell lines at 0.1 MOI, so CV-B5 / Faulkner is selected for oncolytic research.
[0015] To further verify the screening results, we used 100MOI CV-B5 / Faulkner to infect 2BS, MRC-5, KMB-17 and other normal lung tissue cells. The cell survival rate after 24 hours was not statistically significant compared with the control group, and the mortality rate of the three lung cancer cells infected with 100, 10, 1, 0.1, 0.01, and 0.001MOI CV-B5 / Faulkner for 24 hours was dose-dependent.
[0016] Establishing a mouse tumor model is a prerequisite for evaluating the in vivo therapeutic effect of oncolytic viruses. The BALB / c nude mouse CDX lung cancer model established in the present invention uses intratumoral injection of viruses to evaluate the in vivo oncolytic effect of CV-B5. Experiments have shown that when the tumor diameter reaches 4-5 mm, 5 consecutive injections of CV-B5 (5×10 6 TCID 50 / injection) can completely inhibit or even cure NCI-H1299 tumors, and can inhibit the growth of A549 tumors, but rebound will occur when the drug is stopped. It has no obvious therapeutic effect on NCI-H460 tumors. When the diameter of NCI-H1299 tumors reaches 4-5mm (early stage), 1 injection of CV-B5 (5×10 6 TCID 50 ) can completely cure the tumor growth, and there is no rebound after 100 days of observation. When the diameter of NCI-H1299 tumors reaches 8-9mm (late stage), three injections (5×10 6 TCID 50 / needle) can inhibit tumor growth. After drug withdrawal, the tumor volume will continue to increase at a slower rate than the control group, and the survival of the treatment group is significantly longer than that of the control group. Intratumoral injection of oncolytic virus can not only treat lesions at the site of infection, but also play a role in distal targeted treatment of metastases or multiple lesions. This paper established a bilateral NCI-H1299 and A549 tumor-bearing animal model. When the tumor diameter reached 4-5mm, unilateral administration of 5 injections of CV-B5 can cure or significantly inhibit the growth of bilateral tumors. After the mice were cured by intratumoral injection of the virus, no obvious pathological changes appeared in the main organs, proving that the toxic and side effects of CV-B5 were weak. Due to the immunodeficiency of nude mice, it is difficult to evaluate the infiltration of immune cells induced by oncolytic viruses. Therefore, an immune reconstruction animal model was obtained by intraperitoneal injection of human peripheral blood mononuclear cells into β2m KO B-NDG mice, and this model was used to study the therapeutic effect of CV-B5 / Faulkner on the NCI-H1299 CDX model. The results showed that 5 consecutive injections of 5×10 6 TCID 50 CV-B5 / Faulkner can significantly inhibit the growth of NCI-H1299 tumor tissue, and can induce significant infiltration of CD3, CD4, CD8, and granzyme B-positive T cells, as well as tumor cell apoptosis. In addition, since the expression level of CAR in mouse Lewis lung cancer (LLC) and mouse colon cancer cell (CT26.WT) cells is low, we constructed LLC-CAR-LUC and CT26.WT-CAR-LUC cells by stably transfecting CAR receptors and firefly luciferase (LUC) with lentivirus to study the oncolytic effect of CV-B5 / Faulkner in mice with normal natural immune function and the induced lymphocyte infiltration. The experimental results showed that the oncolytic effect of CV-B5 / Faulkner on LLC-CAR-LUC and CT26.WT-CAR-LUC was significantly better than that on wild-type LLC and CT26.WT cells, and the CD4 + T cells, CD8 + The proportions of T cells and NK cells were significantly higher than those in the control group.
[0017] Since the CDX model is quite different from the real tumor tissue, we also used patient-derived tissue to construct a PDX model to further study the oncolytic effect. 6 TCID 50 CV-B5 / Faulkner can significantly inhibit the growth of tumor volume.
[0018] For H460 cells with poor oncolytic effect in vivo, the combined use of DNA-PK inhibitor NU7441 or ATM inhibitor KU60019 and CV-B5 can play a significant synergistic enhancement effect that depends on ER stress (ER stress, ERS). The present invention discovered the oncolytic virus CV-B5 that can selectively kill lung cancer cells through screening and comparison at the cell level, and confirmed that the virus has good selectivity, targeting and therapeutic effects through experiments at the protein level, cell level and in vivo level. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 for the oncolytic effects of CV-B3 / Nancy, CV-B3 / 112, CV-B5 / Faulkner, CV-B5 / JS417, and CV-A6 / Gdula;
[0020] Figure 2 The killing effect of CV-B5 / Faulkner strain on normal lung tissue cells;
[0021] Figure 3 The killing effect of CV-B5 / Faulkner strain on lung cancer cells;
[0022] Figure 4 The oncolytic effect of CV-B5 and the survival time of three lung cancer-bearing nude mice in the early stage of tumors;
[0023] Figure 5 This is the therapeutic effect of different injection times on the early group of NCI-H1299 tumor-bearing nude mice;
[0024] Figure 6 The therapeutic effects and survival time of different injection times of NCI-H1299 tumor-bearing nude mice in the middle and late stage group;
[0025] Figure 7 The distal targeting effect of CV-B5 on nude mice bearing NCI-H1299 and A549 tumors;
[0026] Figure 8 The histopathological changes of major organs of nude mice after intratumoral injection of CV-B5;
[0027] Fig. 9 The effect of CV-B5 / Faulkner on the oncolytic effect of LLC or CT.26WT stably transfected with CAR in vivo and in vitro, and on the percentage of specific T cells and NK cells in tissues;
[0028] Fig.10 The in vivo oncolytic effect of CV-B5 / Faulkner on immune-reconstituted B-NDG mice;
[0029] Fig.11The oncolytic effect of CV-B5 / Faulkner on PDX models;
[0030] Fig.12 The oncolytic effect of CV-B5 / Faulkner combined with NU7441 on different types of tumor cells;
[0031] Fig.13 The enhanced DNA fragmentation effect after the combined use of CV-B5 / Faulkner and NU7441;
[0032] Fig.14 The enhanced DNA fragmentation effect after the combined use of CV-B5 / Faulkner and KU60019;
[0033] Fig.15 The combination of CV-B5 / Faulkner and NU7441 enhances apoptosis and promotes viral replication;
[0034] Fig.16 The combination of CV-B5 / Faulkner and KU60019 enhances apoptosis and promotes viral replication;
[0035] Fig.17 The changes in viral p53 and p21 pathways after the combination of CV-B5 / Faulkner and NU7441 or KU60019;
[0036] Fig.18 The combination of CV-B5 / Faulkner and NU7441 induced PERK activation;
[0037] Fig.19 The combination of CV-B5 / Faulkner and NU7441 induced the activation of PERK downstream;
[0038] Fig. 20 For CV-B5 / Faulkner combined with NU7441, CHOP, pJNK levels increased, and caspase-12 cleavage was observed;
[0039] Fig.21 The synergistically enhanced oncolytic effect at the in vivo level after CV-B5 / Faulkner is used in combination with NU7441 or KU60019. DETAILED DESCRIPTION
[0040] The following examples are used to explain the technical solutions of the present invention in a non-limiting manner.
[0041] In the present invention, unless otherwise specified, "%" used to express concentration or ratio refers to volume percentage.
[0042] In the present invention, the following cells are involved, which can be purchased from the market or obtained from the right holder of the present invention, including: human non-small cell lung cancer cells (A549), human non-small cell lung cancer cells (NCI-H1299), human large cell lung cancer cells (NCI-H460), human hepatoma cells (HepG2), human hepatoma cells (PLC / PRF / 5), human hepatoma cells (Hep3B), human cervical cancer cells (HeLa), human embryonic lung fibroblasts (WI-38), human embryonic lung fibroblasts (HFL-1), human embryonic lung fibroblasts (MRC-5), rhesus monkey kidney cells (LLC-MK2), African green monkey kidney cells (Vero), human rhabdomyosarcoma cells (Rhabdomyosarcoma human pancreatic cancer cells (PANC-1), human pancreatic cancer cells (Bxpc-3), and human pancreatic cancer cells (Capan-1) were preserved by the Cell Resource Collection Center of China Food and Drug Inspection Institutes; human normal liver cells L02 and human normal liver cells MIHA were purchased from ATCC.
[0043] In the present invention, the following viruses are involved. These virus strains are from the prior art or can be purchased. They are subcultured using the corresponding cell lines. After the cells are completely diseased, they are repeatedly frozen and thawed three times, centrifuged at 4000 rpm for 15 minutes at 4°C, filtered, sterilized, packaged and frozen at -80°C. The cell culture infectious dose (CCID) was determined according to the Reed-Muench method. 50 ). The basic information of the virus is shown in Table 1 below:
[0044] Table 1 Basic information of strains
[0045]
[0046] In the present invention, specific-pathogen free (SPF) BALB / c nude mice, BALB / c mice, and C57BL / 6 mice were purchased from the Laboratory Animal Resource Center of the China Food and Drug Inspection Institutes; SPF NPI mice were purchased from Beijing Edmore Biotechnology Co., Ltd.; and SPF B-NDG (β2m KO) mice were purchased from Beijing Biocytogen Pharmaceuticals Co., Ltd.
[0047] The present invention also relates to the following reagents or kits:
[0048] Table 2 Main reagents
[0049]
[0050]
[0051] The present invention also relates to the following culture medium or reagent configuration:
[0052] (1) Western blotting blocking solution: weigh 5 g skim milk powder and dissolve it in 100 ml TBST;
[0053] (2) Antibody working solution: dilute 1000 times with Western blot blocking solution;
[0054] (3) Complete culture medium: Add 50 ml of FBS and 5 ml of penicillin-streptomycin to 500 ml of the corresponding MEM, DMEM or RPMI 1640 culture medium.
[0055] (4) Maintenance culture medium: Add 10 ml of FBS and 5 ml of penicillin-streptomycin double antibody to 500 ml of the corresponding MEM, DMEM or RPMI 1640 culture medium.
[0056] Example 1 Pretreatment
[0057] 1. Cell culture and passaging
[0058] Cell recovery: Take out the cells to be recovered from the liquid nitrogen tank, quickly place them in a 37°C water bath and shake them quickly to form a completely thawed cell suspension. In a biosafety cabinet, dilute the cell suspension to 5 ml with the corresponding complete culture medium (as shown in Table 3 below), centrifuge at 1000 rpm for 5 minutes, discard the supernatant, and then resuspend the cells evenly with the corresponding complete culture medium and transfer them to a T25 cell culture flask for culture at 37°C and 5% CO2.
[0059] Cell passaging: When the cell fusion reaches 90% (some cells reach 70-80%), discard the culture medium, rinse with PBS 2-3 times, add an appropriate amount of trypsin according to the difficulty of cell digestion, and shake evenly. When the cells shrink and begin to fall off, add the corresponding complete culture medium to terminate digestion, and blow evenly until dispersed. Collect the digested cells, centrifuge at 1000rpm for 5min, and discard the supernatant. Add an appropriate amount of complete culture medium to resuspend the cells, and transfer the cells to the culture flask according to the passaging ratio recorded in Table 3.
[0060] Cell freezing: Prepare freezing solution with a volume ratio of 90% FBS and 10% DMSO. Dilute cells to 5×10 6 -1×10 7 The cells were divided into cryopreservation tubes at 100 μl and placed in a cryopreservation box at -80°C overnight. The next day, the cells were transferred to a liquid nitrogen tank for storage.
[0061] Cell counting: Pipette 20 μl of the cell suspension to be counted, add it to the counting pool, and count according to the instructions of the counter. The counted cells are diluted with complete culture medium to the cell amount recorded in Table 3 and plated on a 6-well plate or a 96-well plate.
[0062] Table 3 Culture medium, subculture ratio and plating volume of cells involved
[0063]
[0064] Example 2 Screening of oncolytic coxsackievirus at the cellular level
[0065] Lung cancer cell lines, normal lung tissue cell lines, liver cancer cell lines, normal liver cell lines, and cervical cancer cell lines were used for screening experiments, including 12 types of cells such as A549, NCI-H1299, NCI-H460, WI-38, HFL1, MRC-5, Hep3B, HepG2, PLC / PRF / 5, L02, Hela, and MIHA. The CCK experiment was used to screen the CV-B3 / Nancy, CV-B3 / 112, CV-B5 / Faulkner, CV-B5 / JS417, and CV-A6 / Gdula strains: 96-well plates were plated according to the corresponding cell amounts shown in Table 3, the virus was fused with the cells, and the cell survival rate was obtained.
[0066] Specifically, the virus was serially diluted with the maintenance medium of the corresponding cells (MOI = 0.01, 0.01, 1). After the cell confluence reached 70-80%, the medium was discarded, and the cells were washed 3 times with PBS, and the PBS was discarded. The serially diluted viruses were then added to a 96-well plate, and each dilution was performed in triplicate. At the same time, triplicate negative controls (wells with cell growth, with maintenance solution) and triplicate blank controls (wells without cell growth, with maintenance solution) were set up and placed in a 37°C, 5% CO2 incubator. After 24 / 48h, CCK8 reagent was added, 10μl per well, and when the OD of the negative control wells reached 0.1, the plate was incubated at 40°C and 5% CO2. 450 When the value reaches about 1.0, read the OD 450 value.
[0067] The OD values of the experimental wells, negative control wells, and blank control wells were 450 After taking the average of the values, substitute them into the following formula to calculate the cell survival rate of each well:
[0068]
[0069] The inhibition results of 5 strains on 12 types of cells are as follows Figure 1As shown. The experimental results show that except for CV-A6, which only exhibits a weak cytotoxic effect, the other four virus strains can kill liver cancer cell lines to varying degrees, but the two CV-B3 strains can strongly kill normal liver tissue cell lines, and the two CV-B5 strains have a weak killing effect on normal liver cell lines, so liver cancer cell-sensitive oncolytic viruses are not available; the two CV-B3 strains and the two CV-B5 strains can strongly kill lung cancer cell lines, but CV-B3 can infect and lyse normal lung cell lines, while CV-B5 still cannot kill normal lung tissue cells at MOI=1. Since there is no significant difference in the oncolytic effect of the two CV-B5 strains, CV-B5 / Faulkner was selected as the best oncolytic virus strain for subsequent experiments.
[0070] Example 3 Investigating the cytotoxicity of CV-B5 on normal lung tissue cell lines
[0071] The same experimental method as in Example 2 was used to test the cytotoxicity of CV-B5 to normal lung tissue cell lines, human embryonic lung diploid cells (WI-38), human embryonic lung diploid cells (HFL) and human embryonic lung fibroblasts (MRC-5). The concentration of CV-B5 / Faulkner was continuously increased to 100 MOI, and CCK8 experiments were performed to examine the cytotoxicity of CV-B5 to normal lung tissue cell lines. The results are shown in Figure 2. Figure 2 shown.
[0072] The results showed that 100 MOI of CV-B5 / Faulkner still could not kill normal lung tissue cells, indicating that CV-B5 / Faulkner had no cytotoxicity to normal lung tissue cell lines.
[0073] Example 4 Investigating the relationship between CV-B5 dosage and lung cancer oncolytic effect
[0074] Using the same experimental method as in Example 2, CV-B5 / Faulkner and human non-small cell lung cancer cells (A549), human non-small cell lung cancer cells (NCI-H1299) and human large cell lung cancer cells (NCI-H460) were used as the objects, and the concentration gradient of CV-B5 / Faulkner was MOI=0.0001, 0.001, 0.01, 0.01, 1, 10, 100. CCK8 experiments were performed to examine the dependence of CV-B5 dose on lung cancer oncolytic effect.
[0075] The results are as follows Figure 3 As shown, A549, NCI-H1299, and NCI-H460 cells were infected with 10, 1, 0.1, 0.01, 0.001, and 0.0001 MOI CV-B5 / Faulkner virus for 48 hours, and its cytolytic effect was found to be dose-dependent.
[0076] Example 5 Evaluation of the effect of CV-B5 / Faulkner on lung cancer-bearing nude mice
[0077] 1. Establishment of tumor-bearing mouse model
[0078] (1) Human non-small cell lung cancer cells (A549), human non-small cell lung cancer cells (NCI-H1299), and human large cell lung cancer cells (NCI-H460) were cultured in large quantities in T225 cell culture flasks.
[0079] (2) Four-week-old female BALB / c nude mice were selected and 5×10 6 cells.
[0080] (3) After 7-10 days, the tumor diameter can reach 4-5 mm; 10-15 days after tumor formation, the tumor diameter can reach 15 mm. Ethically, it should be considered that the nude mouse has reached the end of survival.
[0081] 2. Oncolytic effect in the early stage of tumor
[0082] The growth pattern of tumors in mice is similar to that in humans. Initially, the tumor volume will experience a slow growth period (early stage), then enter a rapid tumor growth period (middle stage), and after reaching a certain extent, enter a plateau period (late stage). The evaluation of the oncolytic effect during the slow growth period is an important indicator for the evaluation of viral oncolysis in vivo.
[0083] A549, NCI-H1299, and NCI-H460 tumor-bearing mice were obtained. When the tumor diameter reached 4-5 mm, 5×10 6 TCID 50 CV-B5, a control group was set up at the same time, with no less than 5 mice in each group, injected once every other day for five consecutive times, and the tumor volume was continuously measured and calculated, with the tumor diameter reaching 15mm as the ethical survival endpoint.
[0084] The long and short diameters of the tumor were measured with a vernier caliper every other day from the first injection, and the tumor volume was calculated according to the following formula:
[0085]
[0086] The results are as follows Figure 4 As shown, NCI-H1299 tumor-bearing mice were injected with CV-B5 / Faulkner five times (5×10 6 TCID 50) After 5 injections of CV-B5, the tumor was completely cured, and there was no rebound of the tumor after continuous observation for 60 days; the tumor growth of A549 tumor-bearing mice was significantly inhibited after 5 injections of CV-B5, but rebound occurred after stopping the injection (i.e., 10 days later), but the survival of the treatment group was extended by 5-10 days compared with the control group; the tumor growth rate and survival time of NCI-H460 tumor-bearing mice after 5 injections of CV-B5 were not significantly different from those of the control group. This shows that CV-B5 has no obvious therapeutic effect on NCI-H460 tumor-bearing mice, the therapeutic effect on A549 tumor-bearing mice is limited, and it has a significant effect on NCI-H1299 tumor-bearing mice.
[0087] 3. Oncolytic effects of different injection times in early and late stage tumors
[0088] NCI-H1299 tumor-bearing mice were used as experimental subjects.
[0089] Although oncolytic virus therapy is currently generally administered multiple times to inhibit tumor growth, reducing the dose of the virus without affecting the effect can greatly reduce the patient's pain. Therefore, the oncolytic effect of NCI-H1299 tumor-bearing mice at different growth stages and different injection times was further investigated.
[0090] NCI-H1299 tumor-bearing mice were obtained. Then, early-stage and mid-late-stage groups were set up: when the tumor diameter of the early-stage group reached 4-5 mm, it was divided into 5, 4, 3, 2, and 1 injection groups, with no less than 5 mice in each group, and a control group was set up, with 5×10 6 TCID 50 The virus was injected once every other day. When the diameter of the tumor in the middle and late stage group reached 8-9 mm, the group was divided into 5, 4, and 3 injection groups, and a control group was set up, with no less than 5 mice in each group. 5×10 6 TCID 50 Virus, injected once every other day.
[0091] Early group results Figure 5 As shown, the tumor growth of the five groups was completely inhibited, the tumors of some mice disappeared completely, and there was no rebound trend after 100 days of observation.
[0092] The results of the middle and late stage group were as follows Figure 6 As shown in the figure, the tumor growth of the three groups was completely inhibited. In addition, the tumors in the middle and late stage groups rebounded to varying degrees within a period of time after treatment. The survival curve was drawn from the first treatment to the 60th day, with 15mm as the ethical survival endpoint, as shown in the figure below. Figure 6 As shown, there was no statistical difference in the survival time of mice in the 5-, 4-, and 3-injection treatment groups, but they were all significantly longer than that in the control group.
[0093] 4. Evaluation of the effect of distal targeting application of CV-B5
[0094] A549 and NCI-H1299 cell tumor-bearing mice were used as research subjects.
[0095] Based on the confirmed oncolytic effect of CV-B5 at the injection site, we investigated whether the oncolytic virus has the ability to inhibit the growth of tumors at non-injection sites, thereby investigating the feasibility of applying oncolytic viruses to metastatic or multiple cancers.
[0096] The same method as above was used to construct NCI-H1299 and A549 tumor-bearing mice with bilateral tumor growth. Four-week-old female BALB / c nude mice were selected and 5×10 6 When the tumor diameter reached 4-5 mm, 5×10 6 TCID50 virus, and a control group was set up at the same time, with no less than 5 mice in each group, injected once every other day for five consecutive times. The long and short diameters of bilateral tumors were continuously measured.
[0097] The volume change curves of bilateral tumors in the NCI-H1299 and A549 treatment groups and the control group are shown in Figure 7 As shown, five consecutive unilateral intratumoral injections of CV-B5 completely cured bilateral tumors in early NCI-H1299 tumor-bearing mice; while the growth of bilateral tumors in A549 tumor-bearing mice was significantly inhibited, but there was a rebound phenomenon after drug withdrawal. The experimental results show that CV-B5 can significantly inhibit the proliferation of lung cancer cells in vivo, but due to the different responsiveness of different types of lung cancer cells, it needs to be used in combination with other drugs when used to treat some types of lung cancer.
[0098] Example 6 Histopathological changes of the main organs of nude mice CDX model after intratumoral injection of CV-B5
[0099] The lung, liver, brain, spleen, kidney, heart and pancreas tissues of nude mice injected with five injections were dissected and placed in neutral formalin solution. After fixation, tissue sections were prepared and HE staining was performed. Figure 8 As shown in the figure, except for slight tissue lesions at the site indicated by the arrow, other tissues showed obvious histopathological changes, indicating that CV-B5 / Faulkner has good safety.
[0100] Example 7 The anti-tumor effect of CV-B5 depends on the expression of CAR on the cell surface and can induce significant immune cell infiltration
[0101] The tumor animal model established using nude mice is difficult to evaluate the local immune cell infiltration of the virus-induced tumor, so LLC and CT.26WT cells were used to construct animal models with C57 or BALB / c. However, since the above two cells expressed CAR at a low level, we used lentiviral vectors to construct LLC-CAR and CT26WT-CAR cell lines stably transfected with CAR, and used immunoblotting experiments to confirm the stable expression of CAR. The steps of the immunoblotting experiment are as follows:
[0102] (1) Add 2 μl PMSF to every 100 μl RIPA to obtain protein lysis buffer. Add 50 μl protein lysis buffer to the cell pellet and lyse on ice for 20 min, flicking the pellet 2-3 times.
[0103] (2) Centrifuge at 12000 rpm and 4°C for 15 min, collect the supernatant, and determine the protein content by BCA method.
[0104] (3) Mix the protein and 6×SDS-PAGE loading buffer evenly and heat in a boiling water bath for 15 min.
[0105] (4) Install the electrophoresis tank and load the denatured protein into the wells of the precast gel at a loading volume of 30 μg / well and 10 μl of protein marker.
[0106] (5) Perform electrophoresis at a constant voltage of 120 V until bromocresol blue reaches the bottom of the gel, which should be stopped for about 50 min.
[0107] (6) Soak the nitrocellulose membrane in the electrotransfer solution for 1 min. Place the filter paper, membrane, gel, and filter paper in the order specified on the protein molecule transfer instrument for electrotransfer at 15 V for 15 min.
[0108] (7) After transfer, soak the membrane in blocking buffer and shake at room temperature for 2 h.
[0109] (8) Dilute the antibody according to the instructions using blocking solution to obtain the primary antibody working solution.
[0110] (9) Cut the membrane area to be tested and soak it in working solution, shaking at 4°C overnight.
[0111] (10) Discard the antibody and wash the membrane three times with TBST with oscillation for 10 min each time.
[0112] (11) TBST was discarded and HRP-labeled goat anti-mouse / goat anti-rabbit IgG was diluted 1000-fold to obtain the secondary antibody working solution. The solution was reacted at room temperature for 1 h.
[0113] (12) Repeat step 10.
[0114] (13) Prepare fresh ECL color developing solution, develop the color at room temperature, and read the test results with a multifunctional imager.
[0115] The oncolytic effect of CV-B5 was evaluated using an animal model. Fig. 9 As shown: CV-B5 only has an oncolytic effect on LLC-CAR and CT26WT-CAR cells in vivo. Flow cytometry was also used to study the expression of CD3 + CD4 + T cells, CD3 + CD8 + T cells, CD3 + NK1.1 + Percentage of NK cells, flow cytometry experimental steps:
[0116] (1) Dissect the cancer tissue and digest it with collagenase for 30 minutes, centrifuge at 1000 rpm for 10 minutes, discard the supernatant, wash the precipitate with PBS (containing 1% FBS) three times, separate the mononuclear cells from the precipitate with mouse lymphocyte separation solution, wash it with PBS three times, count the cells, and place them in EP tubes, with no less than 100,000 cells in each tube.
[0117] (2) Take CD3, CD4, CD8, and NK1.1 antibodies and add them to the above cell suspension at a concentration ratio of 1:1000. Incubate at room temperature for 30 minutes in the dark, centrifuge at 1000 rpm for 5 minutes, wash three times with PBS (containing 1% FBS), and finally resuspend with PBS (containing 1% FBS). At the same time, prepare blank cell control tubes and single positive cell tubes with no less than 50,000 cells in each tube.
[0118] (3) Use CELLQuest (BD, USA) software to obtain cells in the blank tube and adjust the fluorescence voltage; then adjust the fluorescence compensation by detecting the single positive tube cells one by one;
[0119] (4) Obtain 30,000 cells from each sample tube and analyze the percentage of each type of cell.
[0120] The results are as follows Fig. 9 As shown, intratumoral injection of CV-B5 can significantly increase the percentage of specific T cells (CD4, CD8) and NK cells in tumor tissue.
[0121] Example 8 CV-B5 treatment of tumor-bearing immune-reconstructed B-NDG mice can induce CD4 + T cells, CD8 + Obvious infiltration of T cells and NK cells
[0122] In addition to using BALB / c nude mice, C57 and BALB / c mice to study the oncolytic effect of CV-B5 in vivo, we also used immune-reconstituted B-NDG mice to evaluate the oncolytic effect and the infiltration of immune cells. Since wild-type B-NDG mice will experience graft-versus-host immune rejection after injection of PBMC, resulting in a shortened window period for the experiment, β2-microglobulin knockout B-NDG mice were used for the experiment. The specific method is as follows: 10 7 One week later, 5 × 10 PBMC were implanted in the axilla 6 NCI-H1299-Luc cells were used. When the tumor volume reached 4-6 mm, 5×10 virus was injected intratumorally. 6 TCID 50 The diary was recorded on the second day (D2), and five viral treatments were given continuously on D4, 6, 8, and 10; and the firefly luciferase substrate was injected intraperitoneally on D3, 5, 7, 9, and 11 to measure the fluorescence intensity. On D12, the tumor was dissected and completely immersed in a neutral formalin solution, tissue sections were made, and immunohistochemical staining was performed, including cleaved-caspase 3, Ki67, CD3, CD4, CD8, Granzyme B, etc. The results are shown in Fig.10 As shown in the figure, the positive reaction degree of Ki67 in the tumor tissue after CV-B5 treatment is low, that is, the positive yellow staining degree is lighter; the positive reaction of cleaved caspase 3 is more, which is manifested as a heavier overall specific cell yellow staining. In addition, as shown by the arrows, only obvious CD3+, CD4+, CD8+, and granulamycin B positive cells were observed in the tumor tissue after CV-B5 treatment. Therefore, compared with the control group, the tumor volume growth in the treatment group was significantly inhibited, and it was mainly through the induction of apoptosis and obvious CD4 + 、CD8 + T cell infiltration is achieved.
[0123] Example 9 Therapeutic Effects of Patient-Derived Tissue Models (PDX)
[0124] The PDX (Patient-derived Xenograft) model refers to a human tumor xenograft model, which is widely used in current work. The PDX model is mainly an animal model constructed by transplanting the patient's tumor tissue or cells into mice, so that human tumors grow in the mice. Because it can fully reflect the various characteristics of the original tumor, this model is currently an important tumor model. In this experiment, NPI mice were used to construct a PDX lung cancer animal model. When the tumor volume reached 4-5mm, CV-B5 / Faulkner was injected intratumorally, 5×10 6 TCID50 , once a day, for a total of five times. The changes in tumor volume were measured. The results are as follows Fig.11 The tumors in the treatment group were significantly inhibited, indicating that CV-B5 / Faulkner has a significant inhibitory effect on human tumors.
[0125] Example 10 Combined use of DNA-PK inhibitor NU7441 at the cellular level can synergistically enhance the anti-tumor effect of CV-B5 on insensitive cells
[0126] According to the results of Example 4 above, the oncolytic effect of CV-B5 alone on NCI-H460 cells was weaker than that on A549 and NCI-NCI-H1299 cells, and the in vivo experimental results of Example 5 showed that five consecutive injections of intratumoral injection had no obvious therapeutic effect on NCI-H460. Therefore, by combining the inhibitors of DNA damage repair, NU7441 or KU60019, whether there is a synergistic enhancement effect was studied.
[0127] Among them, the dose required for using the virus alone is first determined to ensure a low cell killing rate without affecting the effect of the combined use of drugs. From the results of Example 4, it is known that the viability of CV-B5 / Faulkner in treating NCI-H460 cells at 0.01MOI is about 80%, so this dose is selected for the combined drug experiment. NU7441 was diluted to 10μM, 5μM, 2.5μM, 1.25μM, 0.625μM, 0.3125μM, and 0.01MOI CV-B5 / Faulkner was used in combination at each dilution. NCI-H460 cells were infected with different dilution inhibitors (Group 1) or different dilution inhibitors and 0.01MOI CV-B5 / Faulkner mixtures (Group 2), and the cell viability at different dilutions was obtained by CCK8 experiment 24 hours later.
[0128] The cell viability of the inhibitor treatment group (group 1) and the combined use group (group 2) with different dilutions was fitted into curves, and the area under the curve (AUC) was calculated. Then DAUC was calculated:
[0129] DAUC = [AUC (Group 2) - AUC (Group 1)] / AUC (Group 1).
[0130] The calculated DAUC of the NU7441 group was 0.818, indicating that the combination of the two drugs exerted a synergistic effect.
[0131] In addition, the present invention also compares the combined synergistic effect of 1 μM NU7441 and different MOI CV-B5 on various cells. The experimental results are as follows Fig.12NU7441 can enhance the oncolytic effect on p53-expressing cells (PANC-1, NCI-H460, Capan-1, Bxpc-3), but is ineffective against p53-deficient cells (NCI-H1299 and Hep3B).
[0132] Example 11 Combination of NU7441 or KU60019 at the cellular level can significantly promote CV-B5 / Faulkner-induced apoptosis
[0133] The reactive oxygen species induced by CV-B5 / Faulkner replication in cells can promote the double-stranded DNA breaks in the host cell genome. The marker of this process is the increase in pH2AX protein levels, and promotes the phosphorylation of DNA-PK and / or ATM, thereby promoting the recombination repair of non-homologous ends of DNA or homologous recombination repair to avoid the death of host cells. The targets of NU7441 and KU60019 are DNA-PK or ATM. The present invention uses 0.01MOI CV-B5 / Faulkner in combination with 1μM NU7441 or 1μM KU60019 to act on NCI-H460 cells, and uses immunoblotting experiments to detect the phosphorylation levels of DNA-PK, ATM and H2AX in the cells and the protein expression of the virus after 24h (the specific method is the same as the immunoblotting experimental steps in Example 7).
[0134] The results showed that the phosphorylation of DNA-PK and ATM induced by viral replication in cells could be inhibited by NU7441 or KU60019, and promoted the increase of pH2AX level ( Fig.13 , 14 ). In addition, the combination of these two drugs can significantly promote the replication of the virus in the cell, which is manifested by the increase of the viral structural protein VP1, and also promotes the apoptosis caused by the virus ( Fig.15 , 16 ).
[0135] Example 12 Combination of NU7441 or KU60019 at the cellular level can inhibit the activation of the p53 pathway
[0136] The P53 gene is closely related to human tumor suppression. Activated DNA-PK or ATM can induce the activation of the downstream p53 pathway, which is specifically manifested as an increase in the phosphorylation level of p53 (ser15) and the accumulation of downstream p21 protein to promote cell cycle arrest and survival. The emergence of this process is very unfavorable to the oncolytic effect of CV-B5.
[0137] The present invention uses immunoblotting experiments (the specific method is the same as the immunoblotting experiment steps of Example 7) to confirm the activation of the downstream p53 pathway after treatment with 1 μM NU7441 or 1 μM ATM and 0.01 MOI CV-B5. The results show that the combined use of CV-B5 / Faulkner and NU7441 or KU60019 can inhibit the activation of p53 and p21 caused by the virus, thereby promoting cell death ( Fig.17 ).
[0138] For p53-deficient cells, such as NCI-H1299 and Hep3B, CV-B5 cannot induce activation of the p53 pathway, so the combination with NU7441 cannot promote the activation process of the death pathway.
[0139] Example 13 Combination of NU7441 at the cellular level can promote activation of the PERK pathway and promote cell death
[0140] The massive replication of the virus in cells can induce the unfolded protein response of the endoplasmic reticulum, which includes three main pathways, namely IRE1, PERK, and ATF6 pathways. The three pathways can induce phosphorylated IRE1 (pIRE1), phosphorylated PERK (pPERK), and ATF6 (P) to activate and induce cells to produce ERS. If the ERS of the cell is weak, it can be self-relieved by inducing RIDD or peIF2α; if a stronger ERS occurs, it can promote cell death by inducing CHOP, caspase 12, pJNK, etc.
[0141] The present invention detected the expression levels of IRE1, pIRE1, PERK, pPERK, and ATF6 (P) after treatment with 0.01 MOI CV-B5 and 1 μM NU7441 for 24 hours by immunoblotting experiments to reflect the activation of ERS.
[0142] The combined use of NU7441 and CV-B5 / Faulkner in the present invention can induce the activation of the PERK pathway (phosphorylated p-PERK) rather than the IRE1 and ATF6 pathways, and promote the activation of peIF2α and ATF4 downstream of PERK, ultimately promoting the increase of CHOP and pJNK levels and the cleavage of caspase 12 ( Fig.18 , 19, 20).
[0143] Example 14 In vivo experiments: Synergistic enhancement of oncolytic effects of NU7441 or KU60019 on CV-B5 / Faulkner
[0144] Using the nude mouse animal model of Example 5, after the tumor volume reached 4-5 mm, the drugs and viruses were injected intratumorally. The steps were as follows: NU7441 or KU60019 was intraperitoneally injected at a dose of 10 mg / kg / day, and 5×10 6 TCID 50 CV-B5 / Faulkner was injected intratumorally once a day for five consecutive times, and the inhibitor or virus alone was used as a control. The tumor volume was continuously measured, and the curve of tumor volume change over time was drawn to compare the in vivo therapeutic effect of the combined use.
[0145] The results are as follows Fig.21 The combined use of NU7441 or KU60019 can show obvious therapeutic effects.
Claims
1. Use of a combination of Coxsackievirus B group 5 Faulkner strain and a DNA-PK inhibitor in the preparation of a drug for treating pancreatic cancer, characterized in that The DNA-PK inhibitor is NU7441; the drug is used for oncolysis of pancreatic cancer cells expressing p53.
